nVerses Capital LLC grew its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 800.0% within the third quarter, in keeping with the corporate in its most up-to-date submitting with the Securities & Trade Fee. The agency owned 900 shares of the medical analysis firm’s inventory after shopping for an extra 800 shares in the course of the quarter. nVerses Capital LLC’s holdings in Amgen have been value $290,000 as of its most up-to-date SEC submitting.
A variety of different hedge funds have additionally lately modified their holdings of the inventory. Keynote Monetary Providers LLC elevated its holdings in shares of Amgen by 0.6% in the course of the 2nd quarter. Keynote Monetary Providers LLC now owns 4,898 shares of the medical analysis firm’s inventory valued at $1,530,000 after buying an extra 30 shares within the final quarter. Ascent Group LLC elevated its holdings in Amgen by 0.3% within the second quarter. Ascent Group LLC now owns 10,949 shares of the medical analysis firm’s inventory valued at $3,421,000 after shopping for an extra 31 shares within the final quarter. RFP Monetary Group LLC elevated its holdings in Amgen by 17.1% within the first quarter. RFP Monetary Group LLC now owns 219 shares of the medical analysis firm’s inventory valued at $62,000 after shopping for an extra 32 shares within the final quarter. Hofer & Associates. Inc raised its place in shares of Amgen by 0.5% within the second quarter. Hofer & Associates. Inc now owns 6,477 shares of the medical analysis firm’s inventory value $2,024,000 after buying an extra 32 shares in the course of the interval. Lastly, Cadinha & Co. LLC grew its place in shares of Amgen by 0.6% in the course of the third quarter. Cadinha & Co. LLC now owns 5,209 shares of the medical analysis firm’s inventory valued at $1,678,000 after buying an extra 32 shares in the course of the interval. Hedge funds and different institutional buyers personal 76.50% of the corporate’s inventory.
Analyst Rankings Modifications
A variety of equities analysts lately weighed in on AMGN shares. Financial institution of America upped their worth goal on Amgen from $325.00 to $330.00 and gave the inventory a “impartial” ranking in a report on Wednesday, August seventh. Dbs Financial institution upgraded Amgen to a “strong-buy” ranking in a analysis report on Monday, September sixteenth. Deutsche Financial institution Aktiengesellschaft reissued a “maintain” ranking and issued a $305.00 worth goal (down beforehand from $310.00) on shares of Amgen in a report on Wednesday, August seventh. Oppenheimer reaffirmed an “outperform” ranking and set a $380.00 worth goal on shares of Amgen in a report on Wednesday, August seventh. Lastly, Morgan Stanley minimize their goal worth on shares of Amgen from $310.00 to $303.00 and set an “equal weight” ranking for the corporate in a analysis notice on Thursday, July eleventh. One analyst has rated the inventory with a promote ranking, twelve have assigned a maintain ranking, twelve have issued a purchase ranking and one has issued a robust purchase ranking to the corporate. In line with knowledge from MarketBeat.com, the corporate has a median ranking of “Reasonable Purchase” and a median goal worth of $329.48.
Learn Our Newest Inventory Evaluation on AMGN
Amgen Inventory Efficiency
Amgen inventory opened at $321.66 on Friday. The agency has a 50 day easy transferring common of $326.07 and a 200-day easy transferring common of $311.90. The inventory has a market cap of $172.55 billion, a price-to-earnings ratio of 45.95, a price-to-earnings-growth ratio of two.86 and a beta of 0.61. The corporate has a debt-to-equity ratio of 9.64, a present ratio of 1.26 and a fast ratio of 0.89. Amgen Inc. has a 1-year low of $249.70 and a 1-year excessive of $346.85.
Amgen (NASDAQ:AMGN – Get Free Report) final issued its quarterly earnings knowledge on Tuesday, August sixth. The medical analysis firm reported $4.97 earnings per share for the quarter, lacking the consensus estimate of $5.01 by ($0.04). Amgen had a return on fairness of 161.72% and a internet margin of 10.12%. The enterprise had income of $8.39 billion in the course of the quarter, in comparison with analysts’ expectations of $8.35 billion. Throughout the identical quarter within the earlier yr, the corporate posted $5.00 earnings per share. The corporate’s income was up 20.1% on a year-over-year foundation. On common, analysts anticipate that Amgen Inc. will publish 19.49 EPS for the present yr.
Amgen Proclaims Dividend
The enterprise additionally lately introduced a quarterly dividend, which was paid on Tuesday, August sixth. Shareholders of file on Friday, August sixteenth have been paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of two.80%. The ex-dividend date was Friday, August sixteenth. Amgen’s dividend payout ratio (DPR) is presently 128.57%.
Amgen Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The corporate’s principal merchandise embrace Enbrel to deal with plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the therapy of grownup sufferers with plaque psoriasis, psoriatic arthritis, and oral ulcers related to Behçet’s illness; Prolia to deal with postmenopausal ladies with osteoporosis; XGEVA for skeletal-related occasions prevention; Repatha, which reduces the dangers of myocardial infarction, stroke, and coronary revascularization; Nplate for the therapy of sufferers with immune thrombocytopenia; KYPROLIS to deal with sufferers with relapsed or refractory a number of myeloma; Aranesp to deal with a lower-than-normal variety of pink blood cells and anemia; EVENITY for the therapy of osteoporosis in postmenopausal for women and men; Vectibix to deal with sufferers with wild-type RAS metastatic colorectal most cancers; BLINCYTO for the therapy of sufferers with acute lymphoblastic leukemia; TEPEZZA to deal with thyroid eye illness; and KRYSTEXXA for the therapy of power refractory gout.
Learn Extra
Need to see what different hedge funds are holding AMGN? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Obtain Information & Rankings for Amgen Each day – Enter your electronic mail handle under to obtain a concise every day abstract of the newest information and analysts’ scores for Amgen and associated corporations with MarketBeat.com’s FREE every day electronic mail e-newsletter.
